Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
05
09
2019
revised:
31
12
2019
accepted:
27
01
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
Our purpose was to report outcomes in patients with Child-Pugh B or C (CP B/C) hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT). Patients with HCC suitable for SBRT were prospectively enrolled in the study from 2012 to 2018. Outcomes in patients with CP B/C were analyzed. Cox proportional hazard models were used to compare survival outcomes between baseline CP score and post-SBRT CP score. Twenty-three patients with CP B/C with a total of 29 HCC tumors were treated with SBRT. Eighty-seven percent of patients were CP B8-C10. Median tumor size was 3.1 cm (range, 1-10 cm). Median dose delivered was 40 Gy in a median of 5 fractions. Eighteen of 23 patients (78.3%) had been previously treated with transarterial chemoembolization. Median follow-up was 14.5 months. Rates of 6- and 12-month local control were 100% and 92.3%, respectively. Six- and 12-month survival rates were 73.9% and 56.5%, respectively. Median survival was 14.5 months overall and 9.2, 22.5, 14.5, and 14.4 months for patients with CP B7, B8, B9, and C10, respectively. No patients exhibited symptoms of classic radiation-induced liver disease. However, 10 patients had CP score progression, with 4 patients (17%) having a ≥2-point increase in CP score by 6 months (or time of censor). There were 7 liver-related deaths, and based on independent review by a hepatologist, 1 of these deaths may have been attributable to SBRT-related liver injury. Fifteen of 23 patients were listed for liver transplant (LT) at the time of SBRT and 9 went on to receive LT with a pathologic complete response rate of 63.6%. Median survival, excluding patients who received LT, was 7.3 months. SBRT is a reasonable treatment option for carefully selected patients with CP B7-C10. In our small cohort, there was no detectable difference between local control or overall survival and baseline CP score.
Identifiants
pubmed: 33083650
doi: 10.1016/j.adro.2020.01.009
pii: S2452-1094(20)30066-X
pmc: PMC7557134
doi:
Types de publication
Journal Article
Langues
eng
Pagination
889-896Subventions
Organisme : NIAAA NIH HHS
ID : F30 AA024385
Pays : United States
Informations de copyright
© 2020 The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Pract Radiat Oncol. 2015 Sep-Oct;5(5):e443-e449
pubmed: 25899219
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e447-53
pubmed: 21645977
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818790217
pubmed: 30068240
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Pract Radiat Oncol. 2018 May - Jun;8(3):157-166
pubmed: 29426691
J Gastrointest Cancer. 2018 Dec;49(4):463-469
pubmed: 28710606
Ann Surg. 1984 Jun;199(6):648-55
pubmed: 6732310
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9
pubmed: 20171515
Surgery. 1997 Oct;122(4):730-5; discussion 735-6
pubmed: 9347849
Am J Clin Oncol. 2018 Nov;41(11):1118-1124
pubmed: 29553972
Radiother Oncol. 2014 Jun;111(3):412-7
pubmed: 24906626
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Clin Transl Oncol. 2010 Mar;12(3):218-25
pubmed: 20231127
J Clin Oncol. 2013 May 1;31(13):1631-9
pubmed: 23547075
Int J Radiat Oncol Biol Phys. 2018 Jan 6;:
pubmed: 29482870
J Cancer Res Clin Oncol. 2015 Jul;141(7):1301-9
pubmed: 25644863
Hepatology. 1999 Jun;29(6):1617-23
pubmed: 10347099